Azelastine hydrochloride/fluticasone propionate combined in a single nasal spray: a guide to its use in allergic rhinitis

摘要

Azelastine hydrochloride/fluticasone propionate 137/50 ug nasal spray (henceforth MP-AzeFlu) [Dymista?] provides a combination of two first-line treatments for allergic rhinitis, an intranasal antihistamine and an intranasal corticosteroid, in a single spray. In 14-day clinical trials in patients with allergic rhinitis, MP-AzeFlu improved nasal and ocular symptoms to a significantly greater extent than placebo or monotherapy with its individual active components (either marketed products or products re-formulated in the MP-AzeFlu formulation). MP-AzeFlu's novel formulation contributes to its efficacy. MP-AzeFlu provided more rapid relief of symptoms than either azelastine or fluticasone monotherapy, and consistent benefits were demonstrated regardless of disease severity or symptoms. The beneficial effects of MP-AzeFlu have also been shown with long term treatment and in the clinical practice setting. The most frequently reported adverse events with MP-AzeFlu are dysgeusia, epistaxis and headache.